Brincidofovir

Overview

Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir ( HY-17438 ), is an orally available, long-acting antiviral . Brincidofovir shows activity against a broad spectrum of DNA viruses including cytomegalovirus ( CMV ), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > Adenovirus Infection | Products > Disease Areas > Cytomegalovirus Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > CMV | Products > Signaling Pathways > HSV | Products > Signaling Pathways > Orthopoxvirus

Product Information

• Catalog No.: HY-14532
• CAS No.: 444805-28-1
• Molecular Formula: C27H52N3O7P
• Molecular Weight: 561.69
• Purity: 99.72%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source